Using new biological understanding to improve our ability to make better medicines
Kymab was founded with the vision that we could dramatically accelerate both the speed of antibody drug development and improve the quality of antibody medicines. We believe that continued creative innovation is essential to maintaining our leading position and creating unique opportunities.
We are in a uniquely fertile time for genetic discovery and we are alert to new drug targets and the application of genetic knowledge in clinical development. Our ambition is to strengthen our innovative culture, to recognise the long-term competitive advantage and value this culture brings.
We generate our product candidates using our proprietary, integrated technology platforms, collectively called IntelliSelect®
Improving the performance and adaptability of our platforms to enhance their ability to deliver candidate antibodies
With our effective platforms, we have a unique opportunity to generate innovative, high-value bispecific molecules